アレディア
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/01/12 22:20:45」(JST)
[Wiki en表示]
Pamidronic acid
|
Systematic (IUPAC) name |
(3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)
|
Clinical data |
AHFS/Drugs.com |
International Drug Names |
MedlinePlus |
a601163 |
Pregnancy
category |
- AU: B3
- US: D (Evidence of risk)
|
Legal status |
- UK: POM (Prescription only)
- US: ℞-only
|
Routes of
administration |
Intravenous |
Pharmacokinetic data |
Bioavailability |
n/a |
Protein binding |
54% |
Metabolism |
Nil |
Biological half-life |
28 ± 7 hours |
Excretion |
Renal |
Identifiers |
CAS Number |
40391-99-9 Y |
ATC code |
M05BA03 |
PubChem |
CID: 4674 |
IUPHAR/BPS |
7259 |
DrugBank |
DB00282 Y |
ChemSpider |
4512 Y |
UNII |
OYY3447OMC Y |
KEGG |
D07281 Y |
ChEMBL |
CHEMBL834 Y |
Chemical data |
Formula |
C3H11NO7P2 |
Molecular mass |
235.07 g/mol |
SMILES
-
O=P(O)(O)C(O)(CCN)P(=O)(O)O
|
InChI
-
InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11) Y
-
Key:WRUUGTRCQOWXEG-UHFFFAOYSA-N Y
|
(verify) |
Pamidronic acid (INN) or pamidronate disodium (USAN), pamidronate disodium pentahydrate is a nitrogen-containing bisphosphonate, used to prevent osteoporosis. It is marketed by Novartis under the brand name Aredia. In India, it is marketed by Curacell Biotech under the brand name Pamimed.
Contents
- 1 Uses
- 2 Administration
- 3 Side effects
- 4 References
Uses
It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels. It is also used as an experimental treatment of the bone disorder known as Osteogenesis Imperfecta. It has been studied in the treatment of Complex Regional Pain Syndrome.[1]
Administration
Intravenous, usually 90 mg monthly. 30 mg, 60 mg, 90 mg and for hospitals, 120 mg vials are available, mixed with mannitol.
Side effects
Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.[2]
Pamidronate activates human γδ T cells in vitro and in vivo, which may lead to flu-like symptoms upon administration.
References
- ^ Kubalek, O. Fain, J. Paries, A. Kettaneh, M. Thomas (2001). "Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases.". Rheumatology 40 (12): 1394–1397. doi:10.1093/rheumatology/40.12.1394. PMID 11752511.
- ^ Zarychanski R, Elphee E, Walton P, Johnston J (2006). "Osteonecrosis of the jaw associated with pamidronate therapy.". Am J Hematol 81 (1): 73–5. doi:10.1002/ajh.20481. PMID 16369966.
Drugs for treatment of bone diseases (M05)
|
|
Bisphosphonates |
- Nitrogenous (Alendronic acid
- ibandronic acid
- incadronic acid
- pamidronic acid
- risedronic acid
- zoledronic acid)
Non-nitrogenous (Etidronic acid
- clodronic acid
- tiludronic acid)
|
|
Bone morphogenetic proteins |
- Dibotermin alfa
- Eptotermin alfa
|
|
Other |
- Resorption inhibitor (Ipriflavone)
- Aluminium chlorohydrate
- Dual action bone agent (Strontium ranelate)
RANKL inhibitor (Denosumab)
- Cathepsin K inhibitor (Odanacatib)
- Calcium
- Vitamin D
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Diphosphonate Immobilization on Hydroxyapatite-Coated Titanium-Method Description.
- Guimarães MB, Bueno RS, Guimarães Blaya MB, Hirakata LM, Hübler R.Source*Associate Professor of Prosthodontics, School of Dentistry, Centro Universitário Franciscano, Santa Maria, Rio Grande do Sul, Brazil. †Specialist in Implant Dentistry, SOERGS, Porto Alegre, RS, Brazil. ‡Specialist in Orthodontics, PhD in Dental Materials, School of Dentistry, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil. §Associate Professor of Dental Materials, Department of Prosthodontics, School of Dentistry, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil. ¶Assistant Professor of Physics, School of Physics, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
- Implant dentistry.Implant Dent.2013 Jun 3. [Epub ahead of print]
- PURPOSE:: The aim of this study was to promote the immobilization of a bone activity biomodulator (diphosphonate) on titanium, commonly used in implant dentistry, to provide a local method of delivering this drug during the osseointegration process. METHODS:: The implant material used in this study
- PMID 23736311
- Manipulation of autophagy in cancer cells: an innovative strategy to fight drug resistance.
- Aredia F, Scovassi AI.SourceIstituto di Genetica Molecolare CNR, Via Abbiategrasso 207, 27100 Pavia, Italy.
- Future medicinal chemistry.Future Med Chem.2013 Jun;5(9):1009-21. doi: 10.4155/fmc.13.85.
- Autophagy is a catabolic process activated by stress conditions and nutrient deprivation, to which it reacts by promoting the degradation of damaged organelles and misfolded/aggregated proteins, as well as generating new energetic pools. Paradoxically, in cancer cells, which signal the dangerous mic
- PMID 23734684
- Effect of implanted bisphosphonate-enriched cement on the trabecular microarchitecture of bone in a rat model using micro-computed tomography.
- Matuszewski L, Turżańska K, Matuszewska A, Jabłoński M, Polkowska I, Mazurkiewicz T.SourcePaediatric Orthopedic and Rehabilitation Clinic, Medical University of Lublin, Lublin, Poland, lukasz.matuszewski@am.lublin.pl.
- International orthopaedics.Int Orthop.2013 Jun;37(6):1187-93. doi: 10.1007/s00264-013-1855-z. Epub 2013 Mar 16.
- PURPOSE: Bisphosphonates (BPs) are antiresorptive drugs typically used to inhibit bone resorption. The latest reports show that BPs play an important role in not only achieving better bone mineral density but also in improving bone microarchitecture. The mechanism of action of the BPs is complex and
- PMID 23503639
Japanese Journal
- Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws : A growing epidemic
- PSKを併用した bisphosphonate (Aredia) の乳癌細胞株 (c-SST-2) に対する抗腫瘍効果の検討
- Optimising Treatment of Bone Metastases by Aredia^<TM> and Zometa^<TM>
- COLEMAN Robert E.
- Breast cancer : the journal of the Japanese Breast Cancer Society 7(4), 361-369, 2000-10-01
- NAID 10007065983
Related Links
- Generic Name: Pamidronate Drug Type: Aredia is a supportive care drug in the category of bisphosphonates. (For more detail, see "How Aredia Works" section below). What Aredian Is Used For: Aredia is used as a support ...
- Learn about the prescription medication Aredia (Pamidronate Disodium), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. ... What are the possible side effects of pamidronate (Aredia)? Get ...
Related Pictures
![Aredia](https://1mg.info/0/7/b/2629.jpg)
![Aredia](https://1mg.info/0/7/b/2630.jpg)
![Drugs reference index « Aredia »](https://1mg.info/0/7/b/2631.jpg)
![Synonyms: Aredia pamidronate disodium for](https://1mg.info/0/7/b/2632.jpg)
![AREDIA](https://1mg.info/0/7/b/2633.jpg)
★リンクテーブル★
[★]
- 英
- pamidronate、pamidronic acid
- 同
- パミドロネート、パミドロン酸二ナトリウム pamidronate disodium
- 商
- アレディア Aredia
他に分類されない代謝性医薬品